FORMULATION AND IN VITRO EVALUATION OF ENTERIC COATED OMEPRAZOLE TABLETS

S.Bozdağ¹, S.Çalış¹, M.Şumnu¹

¹Department of Pharmaceutical Technology, Faculty of Pharmacy, Hacettepe University, 06100, Ankara-Turkey.

INTRODUCTION

In recent years, omeprazole has been widely employed as a gastric acid secretion blocker and it selectively inhibits the proton pump in the gastric mucosa (1). Omeprazole degrades very rapidly in aqueous solutions at low pH values. The rate of degradation proceeds with a half life of less than 10 minutes at pH values below 4. For this reason, enteric coated formulations has been developed for oral administration to maximise absorption and minimise preabsorption degradation (2).

In this study, various enteric coating solutions with different percentages were performed on subcoated omeprazole tablets; furthermore dissolution tests were realized to determine the appropriate coating ratio.

EXPERIMENTAL

● Preparation of Tablets

Omeprazole (20 mg), lactose (4 %), mannitol (83.5 %) and sodium lauryl sulfate (0.25 %) were mixed in the cylindrical mixer for 10 min. and then granulated with HPMC solution (1 % HPMC in pH 11 phosphate buffer). Granules and microcrystalline cellulose were mixed in the cylindrical mixer. Finally, the magnesium stearate (1%) was added and mixed thoroughly. Tablets were compressed 90 a. eccentric tabletting machine (Erweka, AR 400).

● Coating of Tablets

Subcoating

The tablets were subcoated with HPMC solution (0.25 % HPMC in pH 7.4 phosphate buffer) by the use of fluidized bed apparatus.

Enteric Coating

Previously subcoated tablets were coated with different enteric coating solutions which were prepared from different polymers (Table 1). by the use of fluidized bed apparatus.

Table 1. Ratio of the solutions used for enteric coating.

<table>
<thead>
<tr>
<th>Formulation</th>
<th>Film Former</th>
<th>Plasticizer</th>
<th>Solvent</th>
</tr>
</thead>
<tbody>
<tr>
<td>A₁,₃</td>
<td>HPMC (%)</td>
<td>Dibutil Phthalate* (%)</td>
<td>Acetone-Isopropyl Alcohol (1:1)</td>
</tr>
<tr>
<td>B₁,₃</td>
<td>Eudragit® S-100 (%)</td>
<td>Dibutil Phthalate* (%)</td>
<td>Acetone-Isopropyl Alcohol (1:1)</td>
</tr>
<tr>
<td>C₁,₃</td>
<td>CAP (%)</td>
<td>Dibutil Phthalate* (%)</td>
<td>Acetone-Isopropyl Alcohol (1:1)</td>
</tr>
</tbody>
</table>

* based on dry polymer weight.

● Dissolution Testing

Dissolution rate of enteric coated tablets were determined using USP XXII Apparatus 2 at 37 ± 0.5 °C with paddle and rotation was set at 100 rpm. The dissolution medium was 0.1N HCl solution and pH 7.4 phosphate buffer solution. The drug released in the medium was determined
RESULTS AND DISCUSSION
Omeprazole tablet was designed as an enteric coated dosage form. Thus, it must obey the USP XXII specification; no individual value should exceed 10 % when dissolved in the add phase after 2 hr of operation and no less than 75 % should release in buffer solution after continuous operation on the apparatus for 45 min. The dissolution profiles of enteric coated omeprazole tablets at pH 1.2 and pH 7.4 and the dissolved amount of omeprazole from enteric coated tablet which has enteric coatings at different enteric coating solutions and various percentages were summarized in Figure 1. For the A coded formulations, the released amount of formulation A1 and A2 did not meet the requirements of USP XXII since the dissolved level was less than 75 % and the release amount was more than 10 % in the acidic phase. Meanwhile, the tablet coated by formulation A3 was found to meet USP XXII criteria in both the acid phase and the buffer phase. For B coded formulations (B1, B2, B3), the released amount of formulation did not meet the requirements of USP XXII since the dissolved level was less than 75 % for three of them. But the release amount was less than 10 % in the acidic phase for B3 formulation. Finally, for C coded formulations the data came out to be exactly the same for A coded ones.

As a conclusion, only A3 and C3 sub-coded formulations were determined to be suitable for the objective of our study.

REFERENCES